Company Profile

Industry Sector: Biotechnology

Company Overview: APC Biotechnology Services is a closely held start-up company located in Rockville, Maryland. We have developed an enabling technology that overcomes many of the limitations inherent in the chemical synthesis of long peptides. APC is currently seeking clients for custom peptide synthesis as well as strategic partners and licensees of its technology.

Target Market(s): Companies developing peptide-based diagnostics, therapeutics, and vaccines as well as contract manufacturing organizations (CMO).

Opportunity: APC is currently seeking partners, alliances and licensees with long or difficult peptide products (therapeutics, diagnostics, and vaccines) for which APC’s enabling production platform can add significant value and cost-competitiveness.

Management

Leadership:
Aprile L. Pilon, President and CEO - Over 15 years in leadership of biotech companies.
John K. Zehmer, Director of Research and Development - expert in protein purification and assay development

Advisory Board:
Christine Copple, Ph.D.; CEO Starise Ventures - more than 25 years in senior management of biotech companies; Professional business advisor.
William Bentley, Ph.D.; Professor, chemical engineering, UMD - internationally recognized expert in E. coli protein expression, bioreactor design and optimization.
David Wood, Ph.D.; Associate Professor, chemical engineering, Ohio State - Leading expert in protein engineering and purification.

Key Value Drivers

Technology*: NextPep is a recombinant technology platform for the economic, rapid and scalable manufacture of long peptides and short proteins. The product is expressed in bacteria as a C-terminal extension to our proprietary carrier protein. After an initial purification, the product is liberated by our highly active and specific protease followed by a final purification step.

Competitive Advantages:
- Directly scalable with existing equipment at any CMO.
- Far more economical than chemical synthesis for long peptides.
- Overcomes manufacturing problems of "difficult" peptides.
- Simplified purification - no closely related impurities to remove.
- Reduces or eliminates the use of organic solvents (green technology).

Plan & Strategy: License our enabling technology to our strategic partners

Product Pipeline

NextPep: Manufacturing platform for long peptides and small proteins. Available for contract synthesis and/or licensing.
- Scalable
- Economical
- Rapid
- Green

SpeedVaccs: Platform for the manufacture of subunit vaccines. Under development with proof of concept complete.
- High yield scaffold for display of linear and conformational epitopes
- Co-stimulates humoral and cellular immune response
- No conjugations required
- Stable platform = simplified storage (no cold chain required)